Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Idiopathic short stature: definition, epidemiology, and diagnostic evaluation.

Literature DB >> 18182313

Idiopathic short stature: definition, epidemiology, and diagnostic evaluation.

J M Wit¹, P E Clayton, A D Rogol, M O Savage, P H Saenger, P Cohen.

Abstract

Idiopathic short stature is a condition in which the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population, in whom no identifiable disorder is present. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. It should be differentiated from dysmorphic syndromes, skeletal dysplasias, short stature secondary to a small birth size (small for gestational age, SGA), and systemic and endocrine diseases. ISS is the diagnostic group that remains after excluding known conditions in short children.

Entities: Disease Species

Mesh：

Year: 2008 PMID： 18182313 DOI： 10.1016/j.ghir.2007.11.004

Source DB: PubMed Journal: Growth Horm IGF Res ISSN： 1096-6374 Impact factor: 2.372

Keyword Cloud
Cited

53 in total

1. Exome sequencing and subsequent association studies identify five amino acid-altering variants influencing human height.

Authors: Jae-Jung Kim; Young-Mi Park; Kyu-Heum Baik; Hye-Yeon Choi; Gap-Seok Yang; InSong Koh; Jung-Ah Hwang; Jieun Lee; Yeon-Su Lee; Hwanseok Rhee; Tae Soo Kwon; Bok-Ghee Han; Karen E Heath; Hiroshi Inoue; Han-Wook Yoo; Kiejung Park; Jong-Keuk Lee
Journal: Hum Genet Date: 2011-09-29 Impact factor: 4.132

2. Should idiopathic short stature be treated with growth hormone?

Authors: Martin O Savage
Journal: Nat Clin Pract Endocrinol Metab Date: 2009-03

3. Copy number variants in patients with short stature.

Authors: Hermine A van Duyvenvoorde; Julian C Lui; Sarina G Kant; Wilma Oostdijk; Antoinet C J Gijsbers; Mariëtte J V Hoffer; Marcel Karperien; Marie J E Walenkamp; Cees Noordam; Paul G Voorhoeve; Verónica Mericq; Alberto M Pereira; Hedi L Claahsen-van de Grinten; Sandy A van Gool; Martijn H Breuning; Monique Losekoot; Jeffrey Baron; Claudia A L Ruivenkamp; Jan M Wit
Journal: Eur J Hum Genet Date: 2013-09-25 Impact factor: 4.246

4. Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone.

Authors: Wei Wang; Shuqin Jiang; Zhirui Cui; Xiangyang Luo; Lingli Shi; Heli Zheng
Journal: Front Med Date: 2018-04-06 Impact factor: 4.592

5. Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature: A Phase III Randomised Controlled Trial.

Authors: Woo Yeong Chung; Han-Wook Yoo; Jin Soon Hwang; Cheol Woo Ko; Ho-Seong Kim; Dong-Kyu Jin; Kee-Hyoung Lee; Heon-Seok Han; Premila Paranchothy; Byung-Kyu Suh
Journal: Horm Res Paediatr Date: 2018-08-15 Impact factor: 2.852

10. The Auxological and Biochemical Continuum of Short Children Born Small for Gestational Age (SGA) or with Normal Birth Size (Idiopathic Short Stature).

Authors: Janina Caliebe; David D Martin; Michael B Ranke; Jan M Wit
Journal: Int J Pediatr Endocrinol Date: 2010-05-18

Idiopathic short stature: definition, epidemiology, and diagnostic evaluation.

1. Exome sequencing and subsequent association studies identify five amino acid-altering variants influencing human height.

2. Should idiopathic short stature be treated with growth hormone?

3. Copy number variants in patients with short stature.

4. Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone.

5. Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature: A Phase III Randomised Controlled Trial.

6. Short stature in children: Pattern and frequency in a pediatric clinic, Riyadh, Saudi Arabia.

Review 7. Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

8. BRF1 mutations in a family with growth failure, markedly delayed bone age, and central nervous system anomalies.

9. Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.

10. The Auxological and Biochemical Continuum of Short Children Born Small for Gestational Age (SGA) or with Normal Birth Size (Idiopathic Short Stature).